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Diabetic retinopathyBackground: Diabetic retinopathy (DR) is one of the most common and serious micro vascular complica-
tion affecting type 2 diabetic patients.
The literature on adipokines as a possible mechanism in the pathogenesis of DR is contradictory.
We are in need for more explanation about the pathogenesis of DR and also in need for reliable biomar-
ker for early diagnosis of such complication.
The aim of this work was to study the serum level of omentin-1 and its relation to diabetic retinopathy
in type 2 diabetes mellitus (type 2 DM).
Patients and methods: This study was conducted on 75 type 2 DM patients; 20 healthy subjects served as
a control group. All participants were classified into 4 groups:
 Group1: Included 25 type 2 diabetics without retinopathy.
 Group2: Included 25 type 2 diabetics with non proliferative diabetic retinopathy (NDPR).
 Group 3: Included 25 type 2 diabetics with proliferative diabetic retinopathy (PDR).
 Group 4: Included 20 healthy subjects as a control group.
Thorough history taking and physical examination with calculation of body mass index (BMI), investiga-
tions were done including serum creatinine, lipid profile, glycosylated haemoglobin (HbAIc), C-reactive
protein (CRP), urine albumin creatinine ratio (UACR) and serum omentin-1. Fundus examination was car-
ried out by an expert ophthalmologist.
Results: Serum omentin-1 level was significantly lower in diabetic patients compared with the control,
and in DR compared with diabetics without DR and in PDR compared with NPDR.
There was a negative significant correlation between serum omentin-1 level and BMI, HbA1c, CRP, total
cholesterol, low density lipoprotein (LDL) and Serum triglycerides (TG) and positive significant correla-
tion with high density lipoprotein (HDL).
Conclusions: From this study we can conclude that serum omentin-1 is significantly lower in patients
with DR compared with diabetics without retinopathy and in PDR patients compared with NPDR patients.
Also, there is a negative significant correlation between serum omentin-1 and HbAIc, BMI, CRP and
some lipid parameters.
 2018 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic retinopathy is a leading cause of visual loss in working-
age individuals worldwide, as the prevalence of diabetes mellitus
increases, the development of DR as a micro vascular complication
of diabetes1 mellitus also rises. Furthermore, previous studiesdemonstrated that DR has also been associated with cardiovascular
and all-cause mortality in patients with type 2DM, which adds
value to investigate the risk2,3 factors and early diagnosis for DR.
There are several proposed pathological mechanisms by which
diabetes mellitus may lead to development of retinopathy such as
aldose reductase enzyme, advanced glycated end products, oxida-
tive stress and vascular endothelial growth factor [VEGF].4,5
Omentin-1 is identified adipokine that is preferentially gener-
ated by visceral adipose tissue.6 Omentin-1 plays an anti-
inflammatory role through inhibition of tumor necrosis
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smooth cells.6
Angiogenesis is thought to be one of the underlying mecha-
nisms of diabetic microvascular complications such as diabetic
nephropathy and DR. It was found that omentin-1 decreases
in vitro migration and angiogenesis in human endothelial cells
induced by sera, C-reactive protein and VEGF. Thus omentin-1
appear to be a protective adipokine that it induces vasodilation
and inhibit endothelial cell migration, vascular inflammation and
angiogenesis as well as reducing endothelial dysfunction.7,8
The literature on adipokines as a possible mechanism in the
pathogenesis of DR is contradictory.9,10
The aim of this work is to compare serum levels of omentin-1 in
type 2 diabetes mellitus with and without retinopathy and to
investigate the relationship between serum omentim-1 level and
diabetic retinopathy.2. Patients and methods
A total of 75 T2DM and 20 healthy subjects as a control group
were enrolled in this study, they were classified into 4 groups:
 Group 1: Included 25 T2DM without micro vascular complica-
tions aged 56.5 ± 7.2 years. 12 of them were males and 13 were
females.
 Group 2: Included 25 T2DM had nonproliferative diabetic reti-
nopathy (NPDR) aged 55.9 ± 6.4 years 12 of them were males
and13 were females.
 Group 3: Included 25 T2DM had proliferative diabetic retinopa-
thy (PDR) aged 55.9 ± 8.1 years. 14 of them were males and 11
were females.
 Group 4: included 20 healthy subjects serving as a control
group aged 55.8 ± 6.1 years. 10 of themwere males and 10 were
females.
The patients selected from the inpatient department and out
patient clinics of the Internal Medicine department in Menoufia
University. The selected patients gave consent for participation in
the study before they were exposed to examination and investiga-
tions. The study was conducted from June 2017 to January2018.
The protocol of the study was approved by the ethical committee
of faculty of medicine.
Exclusion criteria
Type I DM, diabetic nephropathy (UACR  30 mg/g creatinine),
diabetic neuropathy, malignancy, acute infection, chronic inflam-Table 1
Comparison between the studied groups as regard demographic and laboratory paramete
Group 1 Group 2 Grou
Age (years) 56.5 ± 7.2 55.9 ± 6.4 55.9 ±
Duration of diabetes (years) 8.6 ± 1.19 9.3 ± 2.4 10.2 ±
Glycosylated hemoglobin (%) 6.8 ± 1.9 7.8 ± 0.8 9.1 ±
Body mass index (kg/m2) 26.6 ± 2.9 28.5 ± 2.8 29.0 ±
Total cholesterol (mg/dl) 190.3 ± 28.1 192.4 ± 28.6 189.8
LDL (mg/dl) 112.8 ± 33.6 122.9 ± 18.8 124.8
HDL (mg/dl) 36.8 ± 7.7 34.5 ± 6.7 33.4 ±
Triglyceride (mg/dl) 154.6 ± 33.6 170 ± 30.7 180.6
C-reactive protein (mg/l) 6.7 ± 1.2 8.4 ± 1.6 10.2 ±
Serum omentin-1 (ng/L) 1332.40 ± 66.24 1115.30 ± 29.45 888.7
Sex
Male (na%) 12 (48%) 12 (48%) 14 (5
Female 13 (52%) 13 (52%) 11 (4
LDL: Low density lipoprotein.
HDL: High density lipoprotein.
Anova test, LSD: Least significant difference.matory diseases, collagen disorders and uncontrolled
hypertension.
All participants were subjected to thorough history with special
emphasis on age, sex and duration of diabetes mellitus. Complete
physical examination performed to all subject with estimation of
weight and height to calculate body mass index. Investigations
included fasting blood glucose, glycosylated hemoglobin, lipid pro-
file, urine analysis, serum creatinine, urine albumin creatinine
ratio, C-reactive protein and serum omentin-1 level was measured
using an enzyme-linked immune sorbent assay.11
Patients under went detailed eye examinations using the early
treatment of diabetic retinopathy study protocol of seven-
standard- field stereoscopic fundus photographs and graded
according to clinical early treatment of diabetic retinopathy study
criteria [no retinopathy, NPDR and PDR].12Statistical methodology
Data were analyses using statistical package for the social
science (SPSS) software computer program, versions. Quantitative
data were presented as mean and SD.
Qualitative data were presented as frequency and percentage.
To compare between groups we used x2 test, analysis of variance
test, and least significant difference.Correlation between two
parameters was made using correlation coefficient. Significance
level value was p equal to or less than 0.05.3. Results
There was no significant difference as regard age and sex
between the studied groups. BMI was significantly higher in dia-
betic groups compared to control group. HbAIC, CRP were signifi-
cantly higher in PDR and NPDR groups compared with diabetic
group without DR and control group.
Serum omentin-1 was significantly lower in diabetic patients
with PDR compared with the other groups, and in NPDR compared
with diabetics without DR and controls (Table 1).
There was a negative significant correlation between serum
omentin-1 concentrations and duration of diabetes, BMI, HbAIc,
CRP, total cholesterol, LDL, TG, and a negative significant correla-
tion with HDL (Table 2).4. Discussion
There are many factors incriminated in the pathogenesis of DR,
such as dysglycemia, insulin resistance, inflammation and angio-
genesis. So, to determine the relation of DR and omentin-1, we alsors.
p 3 Group 4 F-test p LSD
8.1 55.8 ± 6.1 0.050 0.985 –
2.5 – 3.594 0.033* 2,3,vs1
0.9 5.1 ± 0.4 46.370 <0.001* 2,3vs,1
3.5 22.3 ± 2.6 22.371 <0.001* 1,2,3v4, 2,3v1
± 31.4 179.4 ± 30.2 0.823 0.484
± 16.8 120.6 ± 21.4 1.551 0.207
6.9 38.8 ± 7.8 2.469 0.067
± 32.8 144.2 ± 33.7 5.558 0.002* 2,3vs1,4, 3vs1,2
1.4 4.1 ± 1.2 80.045 <0.001* 2,3vs1,4,
3vs1,2
3 ± 21.42 2060 ± 1326.07 13.021 <0.001* 3vs1,2,4,
2vs1,4
X2
6%) 10 (50%) 0.430 0.934 –
4%) 10 (50%)
Table 2





Duration of diabetes 0.450 0.004*
Body mass index 0.467 0.038*
HbAIc 0.877 <0.001*






LDL: Low density lipoprotein.
HDL: High density lipoprotein.
CRP: C-reactive protein.
r: Correlation coefficient.
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lipids profile.
In our study serum omentin-1 levels were significantly
decreased in diabetic groups compared with the control group,
and in diabetics with retinopathy compared with diabetics without
retinopathy, also there was a negative significant correlation
between serum ometim-1 and HbAIc.
Our data in agreement with that of Tan et al.8 who found that:
omentin-1 levels were decreased in subjects with impaired glucose
tolerance, type 1 and type 2 DM, suggesting that omentin-1 is
important for glucose metabolism-invitro, omentin-1 increases
insulin signal transduction by activating the protein kinase B and
enhances insulin-mediated glucose transport in adipocytes.
A clinical study of patients suffering from diabetes mellitus,
reported that serum and vitreous omentin levels were related
to13 the severity of DR, and experimental investigations have
shown that omentin has a potent vasodilatory effect in isolated
vessels mediated by endothelium derived nitric oxide, a strong
vasodilator of the retinal arterioles.8
In our study there was a negative correlation of serum omentin-
1 with total cholesterol, LDL, TG and a positive correlation with
HDL which concurs with14 other studies. Omentin-1 can acti-
vates15,16 S’-AMP protein kinase which works as powerful endoge-
nous cholesterol synthesis inhibitor, and thus we can speculate
that omentin-1 could contribute to regulation of cholesterol syn-
thesis, via this pathway. Although relationship between omentin-
1 and HDL cholesterol is unclear, dysregulation of omentin might
affect the insulin signal, resulting in altered HDL production.17
In the current study, there was a negative significant correlation
between serum omentin-1 and BMI. Some studies have also shown
that omentin-1 serum levels were generally lower in obese groups
with or without type 2 DM.18 In a study performed by de souza
Batista el al.19 plasma levels of omentin were measured in lean,
overweight, and obese, otherwise healthy subjects .The authors
found that plasma omentin levels were highest among the lean
subjects and these levels were inversely correlated with BMI, waist
circumference and insulin resistance.
Also we noticed in our study, a negative significant correlation
between serum omentin-1 and CRP. This finding came in consis-
tency with Tan et al. study.8 A study performed to evaluate the
effects of metformin treatment on omentin-1 levels in polycystic
ovary syndrome subjects and effects of omentin-1 levels on vitro
angiogenesis. They concluded that changes in CRP were signifi-
cantly negatively correlated with changes in serum omemtin-1.
Also Yilmaz et al.20 performed a study to assay the circulating
levels of omentin-1 chemerin and adipsin and examined their
association with clinical, biochemical and histological phenol typesin patients with non-alcoholic fatty liver disease. They found dur-
ing their study that serum omentin-1 levels were significantly
associated with CRP. Some researchers have pointed out21 that
inflammatory factor may have a role in the pathogenesis of
microangiopathy.
CRP is a marker of inflammation and widely used in clinic for
monitoring inflammation.
The role of CRP in diabetic micro angiopathy may be related to
induction of insulin resistance, suppression of nitric oxide synthase
and complement activation.22
In the current study, serum omentin-1 is significantly lower in
PDR compared with NPDR which may indicate the role of
omentin-1in the inhibition of angiogenesis. It was found that
omentin-1 decreases in vitro migration, and angiogenesis in
human endothelial cells induced by sera, C-reactive protein and
VEGF.5
5. Conclusion
Serum omentin-1 is significantly lower in diabetic retinopathy
compared to diabetic without retinopathy and in PDR compared
with NPDR. There is a negative correlation between serum
omentin-1 levels and duration of diabetes. BMI, HbAIc, CRP and
some lipid parameters. So, decreased level of omentin-1 may play
an important role in the pathogenesis and development of DR but
we are still in need for further studies to prove whether serum
omentin-1 level could be used as a biomarker for early diagnosis
of DR and whether offer a new therapeutic opportunity for DR.
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